170 related articles for article (PubMed ID: 27039042)
1. Differential efficacy of the TSPO ligands etifoxine and XBD-173 in two rodent models of Multiple Sclerosis.
Ravikumar B; Crawford D; Dellovade T; Savinainen A; Graham D; Liere P; Oudinet JP; Webb M; Hering H
Neuropharmacology; 2016 Sep; 108():229-37. PubMed ID: 27039042
[TBL] [Abstract][Full Text] [Related]
2. A TSPO ligand is protective in a mouse model of multiple sclerosis.
Daugherty DJ; Selvaraj V; Chechneva OV; Liu XB; Pleasure DE; Deng W
EMBO Mol Med; 2013 Jun; 5(6):891-903. PubMed ID: 23681668
[TBL] [Abstract][Full Text] [Related]
3. Enhancing neurosteroid synthesis--relationship to the pharmacology of translocator protein (18 kDa) (TSPO) ligands and benzodiazepines.
Wolf L; Bauer A; Melchner D; Hallof-Buestrich H; Stoertebecker P; Haen E; Kreutz M; Sarubin N; Milenkovic VM; Wetzel CH; Rupprecht R; Nothdurfter C
Pharmacopsychiatry; 2015 Mar; 48(2):72-7. PubMed ID: 25654303
[TBL] [Abstract][Full Text] [Related]
4. A translocator protein 18 kDa agonist protects against cerebral ischemia/reperfusion injury.
Li HD; Li M; Shi E; Jin WN; Wood K; Gonzales R; Liu Q
J Neuroinflammation; 2017 Jul; 14(1):151. PubMed ID: 28754131
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: Pharmacodynamic studies.
Liere P; Pianos A; Oudinet JP; Schumacher M; Akwa Y
Psychoneuroendocrinology; 2017 Sep; 83():122-134. PubMed ID: 28609670
[TBL] [Abstract][Full Text] [Related]
6. TSPO ligand etifoxine attenuates LPS-induced cognitive dysfunction in mice.
Zhang H; Ma L; Guo WZ; Jiao LB; Zhao HY; Ma YQ; Hao XM
Brain Res Bull; 2020 Dec; 165():178-184. PubMed ID: 33075418
[TBL] [Abstract][Full Text] [Related]
7. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats.
Ugale RR; Sharma AN; Kokare DM; Hirani K; Subhedar NK; Chopde CT
Brain Res; 2007 Dec; 1184():193-201. PubMed ID: 17950705
[TBL] [Abstract][Full Text] [Related]
8. Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury.
Simon-O'Brien E; Gauthier D; Riban V; Verleye M
J Neuroinflammation; 2016 Aug; 13(1):203. PubMed ID: 27565146
[TBL] [Abstract][Full Text] [Related]
9. The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.
do Rego JL; Vaudry D; Vaudry H
PLoS One; 2015; 10(3):e0120473. PubMed ID: 25785994
[TBL] [Abstract][Full Text] [Related]
10. Progesterone treatment modulates mRNA OF neurosteroidogenic enzymes in a murine model of multiple sclerosis.
Garay L; Gonzalez Giqueaux P; Guennoun R; Schumacher M; Gonzalez Deniselle MC; De Nicola AF
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):421-429. PubMed ID: 27597394
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of endocrine responses to the Trier Social Stress Test in Virtual Reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18 kDa (TSPO) ligand etifoxine.
Bahr LM; Maurer F; Weigl J; Weber K; Melchner D; Dörfelt A; Wechsler TF; Bauer O; Reinders J; Milenkovic VM; Wetzel CH; Wetter TC; Rupprecht R; Mühlberger A; Nothdurfter C
Psychoneuroendocrinology; 2021 Feb; 124():105100. PubMed ID: 33338971
[TBL] [Abstract][Full Text] [Related]
12. A TSPO ligand attenuates brain injury after intracerebral hemorrhage.
Li M; Ren H; Sheth KN; Shi FD; Liu Q
FASEB J; 2017 Aug; 31(8):3278-3287. PubMed ID: 28416580
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Neuroprotective Effects of Etifoxine in β-Amyloidinduced Toxicity Models.
Riban V; Meunier J; Buttigieg D; Villard V; Verleye M
CNS Neurol Disord Drug Targets; 2020; 19(3):227-240. PubMed ID: 32479250
[TBL] [Abstract][Full Text] [Related]
14. Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein.
Owen DR; Phillips A; O'Connor D; Grey G; Aimola L; Nicholas R; Matthews PM
Br J Clin Pharmacol; 2022 Sep; 88(9):4230-4236. PubMed ID: 35524344
[TBL] [Abstract][Full Text] [Related]
15. The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity.
Costa B; Cavallini C; Da Pozzo E; Taliani S; Da Settimo F; Martini C
ACS Chem Neurosci; 2017 Jul; 8(7):1448-1454. PubMed ID: 28362078
[TBL] [Abstract][Full Text] [Related]
16. Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options.
Rupprecht R; Pradhan AK; Kufner M; Brunner LM; Nothdurfter C; Wein S; Schwarzbach J; Puig X; Rupprecht C; Rammes G
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1477-1487. PubMed ID: 36574032
[TBL] [Abstract][Full Text] [Related]
17. TSPO Ligands Promote Cholesterol Efflux and Suppress Oxidative Stress and Inflammation in Choroidal Endothelial Cells.
Biswas L; Farhan F; Reilly J; Bartholomew C; Shu X
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477223
[TBL] [Abstract][Full Text] [Related]
18. Reduction of Traumatic Brain Damage by Tspo Ligand Etifoxine.
Shehadeh M; Palzur E; Apel L; Soustiel JF
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31146356
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system expression and PET imaging of the translocator protein in relapsing-remitting experimental autoimmune encephalomyelitis.
Mattner F; Staykova M; Berghofer P; Wong HJ; Fordham S; Callaghan P; Jackson T; Pham T; Gregoire MC; Zahra D; Rahardjo G; Linares D; Katsifis A
J Nucl Med; 2013 Feb; 54(2):291-8. PubMed ID: 23321458
[TBL] [Abstract][Full Text] [Related]
20. Translocator protein as a promising target for novel anxiolytics.
Costa B; Da Pozzo E; Martini C
Curr Top Med Chem; 2012; 12(4):270-85. PubMed ID: 22204481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
